Search Within

Joachim Yahalom

  1. "Department of Pathology and Laboratory Medicine"
Formats
  1. Meeting Abstract (19)
  2. Journal Article (16)
  3. Research Letter (2)
  4. Book Section (1)
Groups
  1. Department of Pathology and Laboratory Medicine (38)
  2. Radiation Oncology, Department of (38)
  3. Survivorship Research (38)
  4. Department of Medicine (34)
  5. Hematologic Malignancies, Division of (32)
  6. Center for Hematologic Malignancies (30)

More Groups

People
  1. Ahmet Dogan (29)
  2. Andrew Zelenetz (22)
  3. Ariela Noy (20)
  4. Alison Moskowitz (19)
  5. Paul Hamlin (19)
  6. Steven Horwitz (19)

More People

Years
  1. 2025 (1)
  2. 2024 (4)
  3. 2023 (9)
  4. 2022 (3)
  5. 2021 (7)
  6. 2020 (4)

More Years

Publications
  1. Blood (10)
  2. Hematological Oncology (7)
  3. Blood Advances (3)
  4. Journal of Clinical Oncology (3)
  5. Blood Cancer Journal (2)
  6. British Journal of Haematology (1)

More Publications

Publishers
  1. American Society of Hematology (13)
  2. Wiley Blackwell (7)
  3. American Society of Clinical Oncology (3)
  4. Nature Publishing Group (3)
  5. Elsevier Inc. (2)
  6. American Association for Cancer Research (1)

More Publishers

Results (38)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genetic alterations in follicular lymphoma predict response to very low dose radiotherapy
    Meeting Abstract

    Wijetunga, N. A.; Lebow, E.; Chan, A.; Lee, J.; Fregonese, B.; Hajj, C.; Cedarquist, G.; Hubbeling, H.; Ma, J.; Sarkar, R.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma
    Journal Article

    Alarcon Tomas, A.; Fein, J. A.; Fried, S.; Flynn, J. R.; Devlin, S. M.; Fingrut, W. B.; Anagnostou, T.; Alperovich, A.; Shah, N.; Fraint, E.; more...
    Leukemia (2023)

    Fulltext@MSK | Save
  • Long-term outcomes of patients with limited-stage ocular adnexal DLBCL treated with combined modality therapy in the rituximab era
    Research Letter

    Qualls, D.; Imber, B. S.; Okwali, M.; Hamlin, P. A.; Kumar, A.; Lahoud, O. B.; Matasar, M. J.; Noy, A.; Owens, C.; Zelenetz, A. D.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Genetic Alterations of CREBBP are associated with radiosensitivity in follicular lymphoma
    Meeting Abstract

    Wijetunga, N. A.; Lebow, E. S.; Lee, J.; Fregonese, B.; Tringale, K. R.; Hubbeling, H.; Sarkar, R.; Ma, J.; Seshan, V.; Joffe, E.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma
    Journal Article

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
    Blood Cancer Journal (2022)

    Fulltext@MSK | Save
  • Favorable outcomes of patients with limited-stage ocular adnexal DLBCL treated in the rituximab era: Long-term follow-up of a single center experience
    Meeting Abstract

    Qualls, D.; Batlevi, C. L.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; Kumar, A.; Matasar, M. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Clinical outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg type treated in the rituximab era: Long-term follow-up of a single-center experience
    Meeting Abstract

    Falchi, L.; Qiu, A.; Ewalt, M. D.; Batlevi, C. L.; Caron, P. C.; Hamlin, P. A.; Hamilton, A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save